Drugs & TargetsFree FDA accepts BLA for biosimilar MYL-1402O in cancer indications March 13, 2020Vol.46 No.11
Drugs & TargetsFree FDA grants Breakthrough Therapy Designation for JNJ-6372 in NSCLC indication March 13, 2020Vol.46 No.11
Drugs & TargetsFree Thermo Fisher Scientific collaborates with Janssen to co-develop companion diagnostic for cancer March 13, 2020Vol.46 No.11
Drugs & TargetsFree European Commission approves Venclyxto in CLL indication March 13, 2020Vol.46 No.11
Clinical RoundupFree FDA encourages inclusion of older adult patients in cancer clinical trials March 13, 2020Vol.46 No.11
Clinical RoundupFree Phase III GY004 for Cediranib and Lynparza doesn’t meet PFS endpoint in ovarian cancer indication March 13, 2020Vol.46 No.11
Clinical RoundupFree Copper IUDs less likely to contribute to cervical cancer than hormonal IUDs March 13, 2020Vol.46 No.11
COVID-19 & CancerFreeTrials & Tribulations A conversation about COVID-19: reflecting on first cases in Kansas March 13, 2020Vol.46 No.11By Roy A. Jensen
Conversation with The Cancer LetterCOVID-19 & CancerFree Is your cancer center ready for COVID-19? March 13, 2020Vol.46 No.11By Alexandria Carolan
COVID-19 & CancerFree Pandemic: Bracing for coronavirus surge March 13, 2020Vol.46 No.11By Alexandria Carolan and Matthew Bin Han Ong
